Loading data
HNGENYSE
| Unit: USD | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 587.86 m USD | 390.4 m USD | 292.73 m USD |
| Cost of revenue | 119.64 m USD | 90.5 m USD | 98.55 m USD |
| Gross profit | 468.22 m USD | 299.9 m USD | 194.18 m USD |
| Research and development expense | 368.14 m USD | 100.84 m USD | 110.06 m USD |
| Operating profit | -546.37 m USD | -31.91 m USD | -130.51 m USD |
| Profit before tax | -527.26 m USD | -11.26 m USD | -108.55 m USD |
| Income tax expense | 998 k USD | 677 k USD | -405 k USD |
| Net income (reported basis) | -528.26 m USD | -11.93 m USD | -108.14 m USD |
| Net income attributable to common shareholders | -424.09 m USD | -11.93 m USD | -108.14 m USD |
| Basic earnings per share | -7.77 USD/share | -0.88 USD/share | -8.31 USD/share |
| Diluted earnings per share | -7.77 USD/share | -0.88 USD/share | -8.31 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.